Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® in Multiple Countries

Medison Pharma United States of America Germany Spain New Zealand Switzerland New York United Kingdom

Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory authorities in more than two dozen countries for various indicationsMedison and Regeneron will work together to continue patient access to this important therapy in select marketsView original content:https://www.prnewswire.co.uk/news-releases/medison-pharma-announces--agreement-with-regeneron-pharmaceuticals-to-commercialize-libtayo-cemiplimab-in-multiple-countries-302028359.html